CD

AEON Biopharma Provides Update on Development Pipeline

Retrieved on: 
Thursday, May 9, 2024
AEON, FDA, Post-traumatic stress disorder, Safety, SGB, Conference, Gastroparesis, Lidocaine, Migraine, IND, Patent, Patient, Torticollis, Toxicity, Pharmaceutical industry

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications.

Key Points: 
  • IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications.
  • Several of these programs are ready to advance into the next stage of clinical development.
  • When taking into consideration our clinical pipeline and combining it with our differentiated business model, we see a number of compelling opportunities to pursue,” said Marc Forth, President and Chief Executive Officer of AEON.
  • Post-Traumatic Stress Disorder (PTSD) - IND-enabling studies are already planned, which are designed to support the development of ABP-450 in PTSD.

Knight Therapeutics Reports First Quarter 2024 Results

Retrieved on: 
Thursday, May 9, 2024
Knight, DLBCL, News, ITP, Health maintenance organization, Hot, Vaginal discharge, Depreciation, Thrombocytopenia, Stomach, Inventory, Collection, Trial of the century, ASCT, Lymphoma, Patient, Acquisition, VVA, IAS, Menopause, Lenalidomide, Absorption, Blue balls, Bookkeeping

Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.

Key Points: 
  • Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.
  • Accounts payable and accrued liabilities: As at March 31, 2024, accounts payable and accrued liabilities were $94,711, an increase of $4,094 or 5%.
  • Cash, cash equivalents and marketable securities: As at March 31, 2024, Knight had $181,859 in cash, cash equivalents and marketable securities, an increase of $20,034 or 12% compared to December 31, 2023.
  • Knight will host a conference call and audio webcast to discuss its first quarter ended March 31, 2024, today at 8:30 am ET.

Furiosa: A Mad Max Saga (Original Motion Picture Soundtrack) Music by Tom Holkenborg Available May 17th

Retrieved on: 
Friday, May 3, 2024
Technology, Entertainment, Audio, Video, Other Entertainment, General Entertainment, TV and Radio, Celebrity, Film & Motion Pictures, Music, WITH, Water, Academy Awards, Survival, IMAX, WaterTower Music, Multimedia, MUSIC, Film industry

WaterTower Music is excited to announce the release of Furiosa: A Mad Max Saga (Original Motion Picture Soundtrack) on May 17th with music by Grammy-nominated multi-platinum producer, musician, composer Tom Holkenborg.

Key Points: 
  • WaterTower Music is excited to announce the release of Furiosa: A Mad Max Saga (Original Motion Picture Soundtrack) on May 17th with music by Grammy-nominated multi-platinum producer, musician, composer Tom Holkenborg.
  • View the full release here: https://www.businesswire.com/news/home/20240503211516/en/
    FURIOSA: A MAD MAX SAGA (ORIGINAL MOTION PICTURE SOUNDTRACK) WITH MUSIC BY TOM HOLKENBORG AVAILABLE MAY 17TH (Graphic: Business Wire)
    The full soundtrack will be available May 17th.
  • Tom Holkenborg’s Furiosa: A Mad Max Saga soundtrack is the follow-up to his widely acclaimed score album from 2015’s Mad Max: Fury Road .
  • Furiosa: A Mad Max Saga is a testament to the vision of a singular film maker, whose pursuit of excellence always inspires me to push my creative limits.”

BOSE INTRODUCES THE SOUNDLINK MAX

Retrieved on: 
Thursday, May 2, 2024
IP67, AAC, Acoustics, Antirrhinum, Android, Phonograph, Distortion, Transducer, SBC, Water, AUX, UV, Dust, Shoulder, Fast Pair, Corrosion, Music, Bass, Satellaview, MP3, Bluetooth, Cassette tape

FRAMINGHAM, Mass., May 2, 2024 /PRNewswire/ -- Today, Bose is turning up the volume on its acclaimed SoundLink Bluetooth® speaker line with the introduction of the SoundLink Max Portable Speaker. This all-new portable speaker has lasting power, rugged durability, and delivers incredible sound for its size. Now you can set the vibe with your favorite playlist no matter where you go.

Key Points: 
  • FRAMINGHAM, Mass., May 2, 2024 /PRNewswire/ -- Today, Bose is turning up the volume on its acclaimed SoundLink Bluetooth® speaker line with the introduction of the SoundLink Max Portable Speaker .
  • The SoundLink Max will be available on May 16th for $399 and can be pre-ordered starting today on Bose.com.
  • The SoundLink Max leverages decades of Bose research in acoustics to deliver incredible performance for your music that will help get the party started and keep it going.
  • The SoundLink Max has a refined design with a powder-coated, silicone-wrapped steel enclosure for a premium look.

Chemung Financial Corporation Reports First Quarter 2024 Net Income of $7.1 million, or $1.48 per share

Retrieved on: 
Thursday, April 18, 2024
Sale, Mastercard, Total, Federal Reserve, Investment, Corporation, CHMG, FHLB, Projection, Federal Home Loan Banks, 190th, Interest, Software, Federal, SBA, NSF, Environment, Unemployment, Chemung Canal Trust Company, CECL, Bank, GDP, Share repurchase, Marketing, Advertising, FOMC, GAAP, Growth, Overalls

Fully taxable equivalent net interest margin was 2.73% in the current quarter, compared to 2.69% in the prior quarter.

Key Points: 
  • Fully taxable equivalent net interest margin was 2.73% in the current quarter, compared to 2.69% in the prior quarter.
  • Non-interest income for the first quarter of 2024 was $5.7 million, compared to $5.9 million for the prior quarter, a decrease of $0.2 million, or 3.4%.
  • Income tax expense for the first quarter of 2024 was $2.0 million, compared to $0.8 million for the prior quarter, an increase of $1.2 million.
  • Income tax expense of $2.0 million for the first quarter of 2024 was comparable with the first quarter of 2023.

Elevance Health and Clayton, Dubilier & Rice Sign Agreement to Launch Strategic Partnership to Advance Primary Care Delivery

Retrieved on: 
Monday, April 15, 2024
General Health, Health, Health Insurance, MPG, Clayton, Dubilier & Rice, Commercial, Elevance Health, Partnership, ELV, Medicare, Dubilier, CD&R, Nursing

Elevance Health, Inc. (NYSE: ELV) and Clayton, Dubilier & Rice (CD&R) announced an agreement to form a strategic partnership to accelerate innovation in primary care delivery, enhance the healthcare experience, and improve health outcomes.

Key Points: 
  • Elevance Health, Inc. (NYSE: ELV) and Clayton, Dubilier & Rice (CD&R) announced an agreement to form a strategic partnership to accelerate innovation in primary care delivery, enhance the healthcare experience, and improve health outcomes.
  • “CD&R’s collaboration with Elevance Health is an important step in our ongoing investment focus to accelerate innovation in care delivery across the country,” said Clay Richards, CD&R Operating Partner.
  • The foundation of the new advanced primary care offering will be stronger patient-provider relationships supported by data-driven insights, care coordination and referral management, and integrated health coaching.
  • apree health, Carelon Health, and MPG offer unique strengths that together promise to improve individuals’ health and wellbeing, while helping care providers deliver higher quality care.

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists

Retrieved on: 
Wednesday, April 10, 2024
Health Technology, Other Health, Technology, Pharmaceutical, Oncology, Mental Health, Philanthropy, Infectious Diseases, Genetics, Artificial Intelligence, Clinical Trials, Foundation, Biotechnology, Science, Research, Health, Eosinophilia, Bronchial hyperresponsiveness, NIMML, Swelling, Choline, PBMC, Gastrointestinal tract, Macrophage, Fibrosis, Red, Atopic dermatitis, Brain, TNF, Inflammation, Phenotype, Abstract, Glycolysis, Lupus, T helper 17 cell, IBD, AAI, Psoriasis, OVA, MASH, Plasma, Fed, Ulcerative colitis, Mouse, COL1A1, Microglia, McCormick Place, Therapy, Carbon tetrachloride, HDM, Immunoglobulin E, IL-6, Medicine, Asthma, House, Neutrophil, Patient, Phagocytosis, Ovalbumin, Rheumatoid arthritis, LANCL2, CDAA, UC

The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.

Key Points: 
  • The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.
  • “We are pleased to present our most recent findings related to the immunometabolic mechanisms of activation of LANCL receptors in inflammation & immunology at this year’s AAI Annual Meeting,” said Dr. Josep Bassaganya-Riera, President and Founding Director of NIMML.
  • NImmune’s portfolio includes first and best-in-class omilancor and NIM-1324, two oral, once-daily agonistic therapeutics that bind and activate the LANCL2 pathway.
  • Title: Pharmacological activation of LANCL2 provides immunometabolic support for the restoration of cognitive function markers in a mouse model of Alzheimer’s disease.

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Retrieved on: 
Friday, April 19, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Ulcerative colitis, TNF, Azathioprine, CDAI, Safety, Education, Food, MD, Burnett School of Medicine, Week, Patient, Methotrexate, UC, Pharmaceutical industry

“Crohn’s disease is a complex and usually progressive disease for which an appropriate management plan is critical.

Key Points: 
  • “Crohn’s disease is a complex and usually progressive disease for which an appropriate management plan is critical.
  • “Our development of a subcutaneous option demonstrates Takeda’s commitment to meeting the very real needs of those living with gastrointestinal diseases.”
    *Please refer to “U.S.
  • FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis”, dated September 27, 2023.
  • Takeda does not expect a material impact on the consolidated financial statements as a result of this approval.

itel Brings Home the Silver in the 2024 Stevie® Awards for Sales & Customer Service for Best Use of Technology and Customer Service Employer of the Year

Retrieved on: 
Wednesday, April 17, 2024
CX, Itel, Stevie Awards, Culture, Customer service, Customer, Multimedia, Silver, Organization, Growth, International business, Online shopping

The Stevie Awards for Sales & Customer Service are the world's top honors for customer service, contact center, business development and sales professionals.

Key Points: 
  • The Stevie Awards for Sales & Customer Service are the world's top honors for customer service, contact center, business development and sales professionals.
  • The Stevie Awards organizes nine of the world's leading business awards programs, also including the prestigious American Business Awards® and International Business Awards®.
  • This year, more than 2,300 nominations were received from 51 nations, from organizations of all sizes, and virtually every industry.
  • The company was also presented with a Silver Stevie® for "Customer Service Employer of the Year", highlighting its significant achievements in employee development and engagement.

State of CI/CD Report: New Findings and Trends from CD Foundation

Retrieved on: 
Tuesday, April 16, 2024
CloudBees, Continuous integration, Linux Foundation, DevOps, Attention, Continuous delivery, Organization, CDF, Music

SEATTLE, April 16, 2024 /PRNewswire/ -- The Continuous Delivery Foundation (CDF), the open source software foundation that seeks to improve the world's capacity to deliver software with security and speed, today announced the latest State of CI/CD Report, at the fifth annual cdCon.

Key Points: 
  • The CD Foundation publishes vendor-neutral data on key DevOps and development metrics, providing insights into where Continuous Integration (CI) and Continuous Delivery (CD) stand in 2024 and beyond.
  • "The CD Foundation has been promoting standards in CD, securing the software supply chain, and advocating for better interoperability.
  • The State of CI/CD Report is an important resource for organizations to understand the performance impact of applying CI/CD practices while highlighting emerging trends.
  • The CD Foundation would like to thank CloudBees for sponsoring this year's report.